On 25th February, 2014, Indian drugmaker Ranbaxy Laboratories Ltd stated that it has suspended all shipments of pharmaceutical ingredients produced at the Toansa and Dewas plants. The step was taken to review processes and controls. Following quality concerns, the shipment to USA has been suspended, which is also expected to affect the European and Indian markets.
Shares of Ranbaxy fell as much as 2.7 per cent in morning trade on the news.
